Increased homocysteine levels correlate with the communication deficit in children with autism spectrum disorder

Psychiatry Research

Volumn 229, Issue 3, 2015, Pages 1031-1037

  Puig Alcaraz, Carmen ^a   Fuentes Albero, Milagros ^b   Calderón, Jesús ^c   Garrote, Dolores ^d   Cauli, Omar ^e  

^a Hospital of Sagunto   (Spain)

^b Hospital Arnau de Villanova   (Spain)

^c Diagnostic Centre Calderón   (Spain)

^d Diagnostic Centre CEDIN   (Spain)

^e UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Autism spectrum disorder; Biomarker; Core symptoms; Homocysteine; Language development; Metabolism

Indexed keywords

3 NITROTYROSINE; BIOLOGICAL MARKER; GLUTATHIONE; HOMOCYSTEINE; METHIONINE; 3-NITROTYROSINE; TYROSINE;

ADOLESCENT; AGE; ARTICLE; AUTISM; CHILD; CLINICAL FEATURE; COMMUNICATION DISORDER; COMORBIDITY; CONTROLLED STUDY; CORRELATIONAL STUDY; DIET; DISEASE ASSOCIATION; DISEASE SEVERITY; DSM-IV; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOCIAL DISABILITY; URINALYSIS; ANALOGS AND DERIVATIVES; COMMUNICATION DISORDERS; COMPLICATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; PRESCHOOL CHILD; URINE;

ADOLESCENT; AUTISM SPECTRUM DISORDER; BIOMARKERS; CHILD; CHILD, PRESCHOOL; COMMUNICATION DISORDERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; GLUTATHIONE; HOMOCYSTEINE; HUMANS; MALE; METHIONINE; TYROSINE;

EID: 84941261032     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.05.021     Document Type: Article

References (55)

1. Adams J.B., Audhya T., McDonough-Means S., Rubin R.A., Quig D., Geis E., Gehn E., Loresto M., Mitchell J., Atwood S., Barnhouse S., Lee W. Effect of a vitamin/mineral supplement on children and adults with autism. BioMed Central Pediatrics 2011, 11:111.
2. Al-Farsi Y.M., Waly M.I., Deth R.C., Al-Sharbati M.M., Al-Shafaee M., Al-Farsi O., Al-Khaduri M.M., Gupta I., Ali A., Al-Khalili M., Al-Adawi S., Hodgson N.W., Ouhtit A. Low folate and vitamin B12 nourishment is common in Omani children with newly diagnosed autism. Nutrition 2013, 29(3):537-541.
3. Alexopoulos P., Topalidis S., Irmisch G., Prehn K., Jung S.U., Poppe K., Sebb H., Perneczky R., Kurz A., Bleich S., Herpertz S.C. Homocysteine and cognitive function in geriatric depression. Neuropsychobiology 2010, 61(2):97-104.
4. Algaidi S.A., Christie L.A., Jenkinson A.M., Whalley L., Riedel G., Platt B. Long-term homocysteine exposure induces alterations in spatial learning, hippocampal signalling and synaptic plasticity. Experimental Neurology 2006, 197(1):8-21.
5. Ali A., Waly M.I., Al-Farsi Y.M., Essa M.M., Al-Sharbati M.M., Deth R.C. Hyperhomocysteinemia among Omani autistic children: a case-control study. Acta Biochimica Polonica 2011, 58(4):547-551.
6. Auer D.P., Pütz B., Kraft E., Lipinski B., Schill J., Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biological Psychiatry 2000, 47(4):305-313.
7. Bertoglio K., Jill James S., Deprey L., Brule N., Hendren R.L. Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. Journal of Alternative and Complementary Medicine 2010, 16(5):555-560.
8. Cauli O., Mansouri M.T., Agusti A., Felipo V. Hyperammonemia increases GABAergic tone in the cerebellum but decreases it in the rat cortex. Gastroenterology 2009, 136(4):1359-1367.
9. Chen C.S., Kuo Y.T., Tsai H.Y., Li C.W., Lee C.C., Yen C.F. Brain biochemical correlates of the plasma homocysteine level: a proton magnetic resonance spectroscopy study in the elderly subjects. The American Journal of Geriatric Psychiatry 2011, 19:618-626.
10. Christie L.A., Riedel G., Platt B. Bi-directional alterations of LTP after acute homocysteine exposure. Behavioral Brain Research 2009, 205(2):559-563.
11. DeVito T.J., Drost D.J., Neufeld R.W., Rajakumar N., Pavlosky W., Williamson P. Evidence for cortical dysfunction in autism: a proton magnetic resonance spectroscopic imaging study. Biological Psychiatry 2007, 61:465-473.
12. Dolske M.C., Spollen J., McKay S., Lancashire E., Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry 1993, 17(5):765-774.
13. Friedman S.D., Shaw D.W., Artru A.A., Dawson G., Petropoulos H., Dager S.R. Gray and white matter brain chemistry in young children with autism. Archives of General Psychiatry 2006, 63:786-794.
14. Frieling H., Röschke B., Kornhuber J., Wilhelm J., Römer K.D., Gruss B., Bönsch D., Hillemacher T., de Zwaan M., Jacoby G.E., Bleich S. Cognitive impairment and its association with homocysteine plasma levels in females with eating disorders -findings from the HEaD-study. Journal of Neural Transmission 2005, 112(11):1591-1598.
15. Frustaci A., Neri M., Cesario A., Adams J.B., Domenici E., Dalla Bernardina B., Bonassi S. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radical Biology and Medicine 2012, 52(10):2128-2141.
16. Frye R.E., Melnyk S., Fuchs G., Reid T., Jernigan S., Pavliv O., Hubanks A., Gaylor D.W., Walters L., James S.J. Effectiveness of methylcobalamin and folinic Acid treatment on adaptive behavior in children with autistic disorder is related to glutathione redox status. Autism Res Treat 2013, 2013:609705.
17. Frye R.E., Rossignol D., Casanova M.F., Brown G.L., Martin V., Edelson S., Coben R., Lewine J., Slattery J.C., Lau C., Hardy P., Fatemi S.H., Folsom T.D., Macfabe D., Adams J.B. A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel. Frontiers in Public Health 2013, 13:1-31.
18. Frye R.E., Rossignol D.A. Treatments for biomedical abnormalities associated with autism spectrum disorder. Frontiers in Pediatrics 2014, 2:66.
19. Gao L., Zeng X.N., Guo H.M., Wu X.M., Chen H.J., Di R.K., et al. Cognitive and neurochemical alterations in hyperhomocysteinemic rat. Neurological Science 2011, 33:39-43.
20. Ghanizadeh A. Increased glutamate and homocysteine and decreased glutamine levels in autism: a review and strategies for future studies of amino acids in autism. Disease Markers 2013, 35(5):281-286.
21. Gonzalez-Liencres C., Tas C., Brown E.C., Erdin S., Onur E., Cubukcoglu Z., Aydemir O., Esen-Danaci A., Brüne M. Oxidative stress in schizophrenia: a case control study on the effects on social cognition and neurocognition. BioMedical Central Psychiatry 2014, 14(1):268.
22. Guevara-Campos J., González-Guevara L., Puig-Alcaraz C., Cauli O. Autism spectrum disorders associated to a deficiency of the enzymes of the mitochondrial respiratory chain. Metabolic Brain Disorders 2013, 28(4):605-612.
23. Guevara-Campos J., González-Guevara L., Cauli O. Autism and intelectual disability associated with mitochondrial disease and hyperlactacidemia. International Journal of Molecular Sciences 2015, 16(2):3870-3884.
24. Harada M., Taki M.M., Nose A., Kubo H., Mori K., Nishitani H. Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR Spectroscopy using a clinical 3 T instrument. Journal of Autism and Developmental Disorders 2011, 41:447-454.
25. Hardan A.Y., Minshew N.J., Melhem N.M., Srihari S., Jo B., Bansal R. An MRI and proton spectroscopy study of the thalamus in children with autism. Psychiatry Research 2008, 163(2):97-105.
26. Hasler G., van der Veen J.W., Tumonis T., Meyers N., Shen J., Drevets W.C. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Archives General of Psychiatry 2007, 64(2):193-200.
27. Ho P.I., Ortiz D., Rogers E., Shea T.B. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity kinase hyperactivation and DNA damage. Journal of Neuroscience Research 2002, 70(5):694-702.
28. Hooshmand B., Solomon A., Kåreholt I., Rusanen M., Hänninen T., Leiviskä J., Winblad B., Laatikainen T., Soininen H., Kivipelto M. Associations between serum homocysteine, holotranscobalamin, folate and cognition in the elderly: a longitudinal study. Journal of Internal Medicine 2012, 271(2):204-212.
29. 1H]MRS study. Translational Psychiatry 2013, 3:e279.
30. James S.J., Cutler P., Melnyk S., Jernigan S., Janak L., Gaylor D.W., Neubrander J.A. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. The American Journal of Clinical Nutrition 2004, 80(6):1611-1617.
31. James S.J., Melnyk S., Fuchs G., Reid T., Jernigan S., Pavliv O., Hubanks A., Gaylor D.W. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. The Americal Journal of Clinical Nutrition 2009, 89(1):425-430.
32. Kalbe E., Schlegel M., Sack A.T., Nowak D.A., Dafotakis M., Bangard C. Dissociating cognitive from affective theory of mind: a TMS study. Cortex 2010, 46:769-780.
33. Kałuzna-Czaplińska J., Michalska M., Rynkowski J. Homocysteine level in urine of autistic and healthy children. Acta Biochimica Polonica 2011, 58(1):31-34.
34. Kaur H., Halliwell B. Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Letters 1994, 350(1):9-12.
35. Lord C., Storoschuk S., Rutter M., Pickles A. Using the ADI-R to diagnose autism in preschool children. Information of Mental Health Journal 1995, 14:234-252.
36. Lowe T.L., Cohen D.J., Miller S., Young J.G. Folic acid and B12 in autism and neuropsychiatric disturbances of childhood. Journal of the American Academy of Child and Adolescent Psychiatry 1981, 20(1):104-111.
37. Main P.A., Angley M.T., Thomas P., O'Doherty C.E., Fenech M. Folate and methionine metabolism in autism: a systematic review. The Americal Journal of Clinical Nutrition 2010, 91(6):1598-1620.
38. Melnyk S., Fuchs G.J., Schulz E., Lopez M., Kahler S.G., Fussell J.J., Bellando J., Pavliv O., Rose S., Seidel L., Gaylor D.W., James S.J. Metabolic imbalance associated with methylation dysregulation and oxidative damage in children with autism. Journal of Autism and Developmental Disorders 2012, 42(3):367-377.
39. MMWR, 2010. Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States. MMWR Surveill Summary 63, pp. 1-21.
40. Moustafa A.A., Hewedi D.H., Eissa A.M., Frydecka D., Misiak B. Homocysteine levels in schizophrenia and affective disorders-focus on cognition. Frontiers in Behavioral Neuroscience 2014, 8:343.
41. Murphy D.G., Daly E., Schmitz N., Toal F., Murphy K., Curran S., et al. Cortical serotonin 5- HT2A receptor binding and social communication in adults with Asperger[U+05F3]s syndrome: an in vivo SPECT study. The American Journal of Psychiatry 2006, 163:934-936.
42. Obeid R., McCaddon A., Herrmann W. The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases. Clinical Chemistry and Laboratory Medicine 2007, 45(12):1590-1606.
43. Parellada M., Moreno C., Mac-Dowell K., Leza J.C., Giraldez M., Bailón C., Castro C., Miranda-Azpiazu P., Fraguas D., Arango C. Plasma antioxidant capacity is reduced in Asperger syndrome. Journal of Psychiatry Research 2012, 46(3):394-401.
44. Paşca S.P., Nemeş B., Vlase L., Gagyi C.E., Dronca E., Miu A.C., Dronca M. High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. Life Sciences 2006, 78(19):2244-2248.
45. Perna A.F., Ingrosso D., De Santo N.G. Homocysteine and oxidative stress. Amino Acids 2003, 25:409-417.
46. Persico A.M., Napolioni V. Urinary p-cresol in autism spectrum disorder. Neurotoxicology Teratology 2013, 36:82-90.
47. Poddar R., Paul S. Novel crosstalk between ERK MAPK and p38 MAPK leads to homocysteine-NMDA receptor-mediated neuronal cell death. Journal of Neurochemistry 2013, 124(4):558-570.
48. Ravaglia G., Forti P., Maioli F., Scali R.C., Saccheitti L., Talerico T., Mantovani V., Bianchin M. Homocysteine and cognitive performance in healthy elderly subjects. Archives of Gerontology and Geriatrics 2004, 9:349-457.
49. Ray B., Long J.M., Sokol D.K., Lahiri D.K. Increased secreted amyloid precursor protein-α (sAPPα) in severe autism: proposal of a specific anabolic pathway and putative biomarker. PLoS One 2011, 6(6):e20405.
50. Selley M.L. Homocysteine increases the production of asymmetric dimethylarginine in cultured neurons. Journal of Neuroscience Research 2004, 77(1):90-93.
51. Shi Q., Savage J.E., Hufeisen S.J., Rauser L., Grajkowska E., Ernsberger P., Wroblewski J.T., Nadeau J.H., Roth B.L. L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists. Journal of Pharmacology and Experimental Therapeutics 2003, 305(1):131-142.
52. Tu W.J., Chen H., He J. Application of LC-MS/MS analysis of plasma amino acids profiles in children with autism. Journal of Clinical Biochemistry and Nutrition 2012, 51(3):248-249.
53. West P.R., Amaral D.G., Bais P., Smith A.M., Egnash L.A., Ross M.E., Palmer J.A., Fontaine B.R., Conard K.R., Corbett B.A., Cezar G.G., Donley E.L., Burrier R.E. Metabolomics as a tool for discovery of biomarkers of autism spectrum disorder in the blood plasma of children. PLoS One 2014, 9(11):e112445.
54. West R.K., Beeri M.S., Schmeidler J., Mitchell D.B., Carlisle K.R., Angelo G., Mavris R., Langhoff E., Rosendorff C., Silverman J.M. Homocysteine and cognitive function in very elderly nondemented subjects. The American Journal of Geriatric Psychiatry 2011, 19(7):673-677.
55. Zeidán-Chuliá F., de Oliveira B.H., Salmina A.B., Casanova M.F., Gelain D.P., Noda M., Verkhratsky A., Moreira J.C. Altered expression of Alzheimer[U+05F3]s disease-related genes in the cerebellum of autistic patients: a model for disrupted brain connectome and therapy. Cell Death and Disorders 2014, 5:e1250.